Opyl Signs Definitive Services Agreement with Innovatrix Capital

Opyl Ltd (ASX: OPL) has formalised its partnership with UK-based Innovatrix Capital Ltd through a definitive Services Agreement, cementing the role of its proprietary AI platform, TrialKey, as the exclusive independent Calculation Agent for Innovatrix’s clinical trial failure insurance products. This milestone validates TrialKey’s commercial potential in the global life sciences insurance market while providing Opyl with continuous access to diverse clinical trial datasets and structured user feedback to enhance predictive accuracy.

TrialKey’s Probability of Success (PoS) insights will be integrated into Innovatrix’s CliniX rating engine, supporting underwriting, pricing, and claims processes. The collaboration opens global market exposure through Innovatrix’s network of biotech sponsors, CROs, insurers, and capital providers. With over 65,000 trials launched annually and failure rates nearing 90%, the partnership aims to address a significant gap in trial design and risk management. Opyl anticipates revenue from service delivery and further growth opportunities in AI-driven drug discovery and trial optimisation.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com